Search company, investor...
Iota Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised


About Iota Biosciences

Iota Biosciences aims to change how the world monitors and treats disease. Building on 'neural dust' technology, it is building a platform for the future of bioelectronic medicine.On October 15, 2020 Iota Biosciences was acquired by Astellas Pharma.5M to acquire the remainder of shares.

Iota Biosciences Headquarters Location

1936 University Ave Suite 355

Berkeley, California, 94704,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Iota Biosciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Iota Biosciences in 1 CB Insights research brief, most recently on Aug 6, 2020.

Expert Collections containing Iota Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Iota Biosciences is included in 5 Expert Collections, including Medical Devices.


Medical Devices

8,483 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health Monitoring & Diagnostics

2,406 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Digital Health

13,113 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

Iota Biosciences Patents

Iota Biosciences has filed 7 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Peripheral nervous system disorders
  • Neurophysiology
patents chart

Application Date

Grant Date


Related Topics




Implants (medicine), Peripheral nervous system disorders, Neurophysiology, Neurotechnology, Neuroprosthetics


Application Date


Grant Date



Related Topics

Implants (medicine), Peripheral nervous system disorders, Neurophysiology, Neurotechnology, Neuroprosthetics



Latest Iota Biosciences News

GSK, Verily-backed Galvani starts trials of bioelectronic arthritis therapy

Jan 27, 2022

January 27, 2022 The first patient has been treated with an implantable bioelectronic device developed by Galvani Therapeutics, set up by GlaxoSmithKline and Alphabet’s Verily Life Sciences in 2016. A rheumatoid arthritis patient has become the first of five to be implanted with the wireless device in the UK study – using keyhole surgery at the NHS Greater Glasgow & Clyde Health Board in Scotland last November – in a first step towards treating chronic diseases by modifying nerve signals to organs in the body. In the last month, the device was activated, marking the start of the treatment after a period to make sure the device was stable and well-tolerated. Galvani is using its device to stimulate the splenic nerve, which sends signals to the spleen. Lab studies have suggested that this type of stimulation can alter immune cells made in the spleen switching them from a pro-inflammation to an anti-inflammation state. The spleen is the largest lymphatic organ in the body, and the hope is that the reprogrammed immune cells will migrate to areas affected by rheumatoid arthritis and dampen down the inflammatory response. The first subject had the device implanted in a procedure lasting around an hour, with the neurostimulator attached to the wall of the body cavity in the abdomen. The delivery of electrical pulses is programmed by the treating physician using an app, and patients can monitor and control their therapy and charge their implant wirelessly. Galvani is now preparing for a larger US study in 28 people with rheumatoid arthritis that will run at sites in Texas, Alabama and New York City. In that trial, patient will be randomised to the Galvani device or sham stimulation. The device is being developed initial for patients with rheumatoid arthritis who do not respond well to current treatments like disease-modifying antirheumatic drugs (DMARDs) and biologics, or who suffer side effects that limit their use. GSK was an early mover in bioelectronics, setting up a dedicated research unit in 2012 and launching a $50 million fund to support startups working in this area a year later, plus a $1 million prize fund for promising research projects. Partnering with Verily to form Galvani was a major milestone in the path to making bioelectronic therapies a reality, allowing work to start on miniaturising the neurostimulator and the development of the controlling software. Now, the start of human trials now means that the technology could be just a few years away from the market. Other pharma players are also getting involved in the bioelectronics sector, including Astellas which bought Iota Biosciences in a deal worth up to $429 million in 2020, taking control of its ultrasound-powered implantable neurostimulator technology. Don't miss your daily pharmaphorum news.

  • When was Iota Biosciences founded?

    Iota Biosciences was founded in 2017.

  • Where is Iota Biosciences's headquarters?

    Iota Biosciences's headquarters is located at 1936 University Ave, Berkeley.

  • What is Iota Biosciences's latest funding round?

    Iota Biosciences's latest funding round is Acquired.

  • How much did Iota Biosciences raise?

    Iota Biosciences raised a total of $15M.

  • Who are the investors of Iota Biosciences?

    Investors of Iota Biosciences include Astellas Pharma, Horizons Ventures, Astellas Venture Management, Ironfire Ventures, BOLD Capital Partners and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.